SAN DIEGO, May 10, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that
Amit D. Munshi, President and Chief
Executive Officer, will present at the following investor
conferences:
- Bank of America Merrill Lynch Healthcare Conference in
Las Vegas, NV on Thursday, May 17 at 11:35
a.m. PDT
- UBS Global Healthcare Conference in New York, NY on Tuesday, May 22, 2018 at 9:30 a.m. EDT
A live audio webcast of the presentations will be available
under the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on delivering novel, transformational medicines with
optimized pharmacology and pharmacokinetics to patients globally.
Arena's proprietary pipeline includes multiple potentially first-
or best-in-class programs with broad clinical utility. The most
advanced investigational clinical programs are ralinepag (APD811),
which will be commencing a Phase 3 program for pulmonary arterial
hypertension (PAH), and etrasimod (APD334), which will be
commencing a Phase 3 program for ulcerative colitis (UC) and a
program in Crohn's Disease (CD), and which has potential utility
for a broad range of immune and inflammatory conditions. Arena is
also evaluating olorinab (APD371) in Phase 2 for the treatment of
visceral pain associated with Crohn's disease, as well as other
drug candidates in earlier research and development stages.
In addition, Arena has several collaborations including Everest
Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "upcoming," "will," "focused on,"
"potentially," "potential," or words of similar meaning, or by the
fact that they do not relate strictly to historical or current
facts. Such forward-looking statements include statements about the
upcoming presentations and about Arena's focus, programs and
collaborations. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include that clinical programs may not
proceed at the time or in the manner expected or at all, as well as
those factors disclosed in Arena's filings with the Securities and
Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims
any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-upcoming-investor-conferences-300646087.html
SOURCE Arena Pharmaceuticals, Inc.